Загрузка...
Building a CAR Garage: Preparing for the delivery of commercial CAR T products at Memorial Sloan Kettering Cancer Center.
Two commercial Chimeric Antigen Receptor (CAR) T cell therapies for CD19 expressing B cell malignancies, Kymriah and Yescarta, have recently been approved by the FDA. The administration of CAR T cells is a complex endeavor involving cell manufacture, tracking and shipping of apheresis products, and...
Сохранить в:
| Опубликовано в: : | Biol Blood Marrow Transplant |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6625528/ https://ncbi.nlm.nih.gov/pubmed/29499327 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2018.02.018 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|